Nanoparticle–Hydrogel System for Post-myocardial Infarction Delivery of MicroRNA
Source abstract
Abstract
Effective therapies for cardiac repair and regeneration after myocardial infarction (MI) are rather limited. Although microRNAs (miRs) are known to play an important role in improving cardiac function after MI at a cellular level, delivering and retaining miRs at the target site has been challenging. To address this dilemma, several miR carriers have been developed, but these face their own limitations such as immunogenicity and poor targeting to the infarct site. In this Perspective, we summarize different mechanisms for miR administration and localization to cardiac tissue, with a specific focus on the clinically relevant injectable hydrogel and nanoparticle system developed by Yang et al. and reported in this issue of ACS Nano. We also highlight future directions for this field and outline the remaining unanswered questions.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Tissue Engineering and Regenerative Medicine · Electrospun Nanofibers in Biomedical Applications · MicroRNA in disease regulation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, Georgia 30322, United States
References (37)
Show source-provided references
1. 10.1161/CIR.000000000000065910.1161/CIR.0000000000000659 ↗
2. 10.1016/j.pharmthera.2009.10.00310.1016/j.pharmthera.2009.10.003 ↗
3. 10.5732/cjc.011.1018610.5732/cjc.011.10186 ↗
4. 10.1007/s10616-016-9952-710.1007/s10616-016-9952-7 ↗
5. 10.1002/adhm.20160104110.1002/adhm.201601041 ↗
6. 10.1021/acsnano.9b0334310.1021/acsnano.9b03343 ↗
7. 10.1038/nrg137910.1038/nrg1379 ↗
8. 10.1155/2019/574260810.1155/2019/5742608 ↗
9. 10.1038/nrcardio.2014.20710.1038/nrcardio.2014.207 ↗
10. 10.1161/CIRCRESAHA.112.30080610.1161/CIRCRESAHA.112.300806 ↗
11. 10.1172/JCI5932710.1172/JCI59327 ↗
12. 10.1161/CIRCRESAHA.112.30065810.1161/CIRCRESAHA.112.300658 ↗
13. 10.1038/nature1173910.1038/nature11739 ↗
14. 10.1161/CIRCULATIONAHA.109.92842410.1161/CIRCULATIONAHA.109.928424 ↗
15. 10.1093/cvr/cvu16710.1093/cvr/cvu167 ↗
16. 10.1093/nar/gkg39310.1093/nar/gkg393 ↗
17. 10.1007/s00216-018-1032-810.1007/s00216-018-1032-8 ↗
18. 10.1093/nar/gkq127010.1093/nar/gkq1270 ↗
19. 10.1593/neo.10137210.1593/neo.101372 ↗
20. 10.2147/IJN.S20783710.2147/IJN.S207837 ↗
21. 10.2147/IJN.S7959810.2147/IJN.S79598 ↗
22. 10.21037/sci.2017.11.0610.21037/sci.2017.11.06 ↗
23. Vannucci L. · New Microbiol. · 2013 · 36 · 1
24. 10.2147/IJN.S6886110.2147/IJN.S68861 ↗
25. 10.1016/j.ejpb.2018.04.01810.1016/j.ejpb.2018.04.018 ↗
26. 10.1016/j.jconrel.2018.11.00410.1016/j.jconrel.2018.11.004 ↗
27. 10.1016/j.jtcvs.2018.07.11710.1016/j.jtcvs.2018.07.117 ↗
28. 10.1002/adfm.20160560910.1002/adfm.201605609 ↗
29. 10.1038/aps.2017.1210.1038/aps.2017.12 ↗
30. Hodne K. · 2017 · 16910.1007/978-1-4939-6588-5_11 ↗
31. 10.1016/0092-8674(89)90417-010.1016/0092-8674(89)90417-0 ↗
32. ClinicalTrials.gov [internet] (US). 2019 Oct 20–Identifier NCT02580552, Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients with Mycosis Fungoides (MF), CLL, DLBCL or ATLL; 2019 June 25. Available from: https://clinicaltrials.gov/ct2/show/NCT02580552?term=Cobomarsen&rank=3#contacts (accessed August 12, 2019).
33. ClinicalTrials.gov [internet] (US). 2010 Sept 13–Identifier NCT01200420, Multiple Ascending Dose Study of Miravirsen in Treatment-Naïve Chronic Hepatitis C Subjects; 2012 Jan 13. Available from: https://clinicaltrials.gov/ct2/show/NCT01200420?term=Miravirsen&rank=4 (accessed August 13, 2019).
34. 10.1016/j.nano.2016.12.00910.1016/j.nano.2016.12.009 ↗
35. 10.1242/jcs.07752910.1242/jcs.077529 ↗
36. 10.7554/eLife.2560510.7554/eLife.25605 ↗
37. 10.1038/s41467-018-04908-z10.1038/s41467-018-04908-z ↗